marketcaparena
Search

    TMO

    THERMO FISHER SCIENTIFIC INC.

    Company overview

    Market capitalization
    $250.91B
    Employees
    125,000
    Latest publication
    2026-09-29
    About THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It has strategic collaboration with genedrive plc to develop a CYP2C19 pharmacogenetic in vitro diagnostic test. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-27 · USDQ1 20262026-03-28 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue11,994,000,000USD11,005,000,000USD12,215,000,000USD11,122,000,000USD10,855,000,000USD10,364,000,000USD11,395,000,000USD10,598,000,000USD
    Cost Of Revenue7,112,000,000USD6,575,000,000USD7,579,000,000USD6,470,000,000USD6,807,000,000USD6,119,000,000USD6,928,000,000USD6,255,000,000USD
    Gross Profit4,882,000,000USD4,430,000,000USD4,636,000,000USD4,652,000,000USD4,048,000,000USD4,245,000,000USD4,467,000,000USD4,343,000,000USD
    Research Development364,000,000USD336,000,000USD357,000,000USD347,000,000USD352,000,000USD342,000,000USD374,000,000USD346,000,000USD
    Selling General Administrative2,333,000,000USD2,181,000,000USD1,977,000,000USD2,162,000,000USD1,779,000,000USD2,078,000,000USD2,203,000,000USD2,098,000,000USD
    Total Operating Expenses2,795,000,000USD2,567,000,000USD2,334,000,000USD2,712,000,000USD2,131,000,000USD2,405,000,000USD2,199,000,000USD2,427,000,000USD
    Operating Income2,087,000,000USD1,863,000,000USD2,302,000,000USD1,943,000,000USD1,917,000,000USD1,840,000,000USD2,268,000,000USD1,916,000,000USD
    Total Other Income Expense Net-163,000,000USD-129,000,000USD-179,000,000USD-115,000,000USD-206,000,000USD-234,000,000USD-294,000,000USD-188,000,000USD
    Interest Income207,000,000USD233,000,000USD107,000,000USD234,000,000USD107,000,000USD203,000,000USD227,000,000USD277,000,000USD
    Interest Expense401,000,000USD354,000,000USD365,000,000USD347,000,000USD404,000,000USD303,000,000USD384,000,000USD424,000,000USD
    Income Before Tax1,924,000,000USD1,734,000,000USD2,123,000,000USD1,828,000,000USD1,711,000,000USD1,606,000,000USD1,974,000,000USD1,728,000,000USD
    Income Tax Expense167,000,000USD70,000,000USD153,000,000USD207,000,000USD92,000,000USD95,000,000USD150,000,000USD99,000,000USD
    Equity Method Income Loss-15,000,000USD-8,000,000USD——————
    Net Income1,741,000,000USD1,656,000,000USD1,975,000,000USD1,616,000,000USD1,617,000,000USD1,507,000,000USD1,830,000,000USD1,630,000,000USD
    Minority Interest5,000,000USD5,000,000USD-6,000,000USD-5,000,000USD-2,000,000USD-4,000,000USD6,000,000USD0USD
    Net Income Applicable To Common Shares1,736,000,000USD1,651,000,000USD1,964,000,000USD1,616,000,000USD1,617,000,000USD1,507,000,000USD1,830,000,000USD1,630,000,000USD
    Net Interest Income——-107,000,000USD-113,000,000USD-107,000,000USD-100,000,000USD-90,000,000USD-79,000,000USD
    Tax Provision——153,000,000USD207,000,000USD92,000,000USD95,000,000USD150,000,000USD99,000,000USD
    Net Income From Continuing Ops——1,970,000,000USD1,621,000,000USD1,618,000,000USD1,511,000,000USD1,824,000,000USD1,629,000,000USD
    Ebit——2,488,000,000USD2,175,000,000USD2,113,000,000USD1,923,000,000USD2,326,000,000USD2,166,000,000USD
    Ebitda——3,215,000,000USD2,838,000,000USD2,798,000,000USD2,628,000,000USD3,068,000,000USD2,906,000,000USD
    Depreciation And Amortization——727,000,000USD663,000,000USD685,000,000USD705,000,000USD742,000,000USD740,000,000USD
    Reconciled Depreciation——728,000,000USD661,000,000USD686,000,000USD705,000,000USD742,000,000USD739,000,000USD
    Unclassified Operating Expenses———203,000,000USD——-378,000,000USD—
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USDFY 20172017-12-31 · USD
    Total Revenue44,556,000,000USD42,879,000,000USD44,915,000,000USD39,211,000,000USD32,218,000,000USD25,542,000,000USD24,358,000,000USD20,918,000,000USD
    Cost Of Revenue26,318,000,000USD25,151,000,000USD25,904,000,000USD19,577,000,000USD16,191,000,000USD14,198,000,000USD13,370,000,000USD11,239,000,000USD
    Gross Profit18,238,000,000USD17,728,000,000USD19,011,000,000USD19,634,000,000USD16,027,000,000USD11,344,000,000USD10,988,000,000USD9,679,000,000USD
    Research Development1,397,000,000USD1,390,000,000USD1,471,000,000USD1,406,000,000USD1,181,000,000USD1,003,000,000USD967,000,000USD888,000,000USD
    Selling General Administrative8,732,000,000USD8,595,000,000USD7,127,000,000USD6,842,000,000USD6,930,000,000USD6,144,000,000USD6,057,000,000USD5,492,000,000USD
    Total Operating Expenses10,492,000,000USD10,066,000,000USD10,486,000,000USD9,316,000,000USD8,130,000,000USD7,085,000,000USD7,116,000,000USD6,412,000,000USD
    Operating Income7,746,000,000USD7,662,000,000USD8,525,000,000USD10,318,000,000USD7,897,000,000USD4,259,000,000USD3,872,000,000USD3,267,000,000USD
    Total Other Income Expense Net-438,000,000USD-667,000,000USD-862,000,000USD-1,481,000,000USD-670,000,000USD-189,000,000USD-610,000,000USD-838,000,000USD
    Interest Income993,000,000USD1,078,000,000USD272,000,000USD43,000,000USD488,000,000USD224,000,000USD137,000,000USD81,000,000USD
    Interest Expense1,419,000,000USD1,654,000,000USD726,000,000USD536,000,000USD553,000,000USD676,000,000USD667,000,000USD592,000,000USD
    Income Before Tax7,308,000,000USD6,995,000,000USD7,663,000,000USD8,837,000,000USD7,227,000,000USD4,070,000,000USD3,262,000,000USD2,429,000,000USD
    Income Tax Expense547,000,000USD657,000,000USD703,000,000USD1,109,000,000USD850,000,000USD374,000,000USD324,000,000USD201,000,000USD
    Equity Method Income Loss-41,000,000USD———————
    Net Income6,721,000,000USD6,335,000,000USD6,950,000,000USD7,725,000,000USD6,375,000,000USD3,696,000,000USD2,938,000,000USD2,225,000,000USD
    Minority Interest17,000,000USD-3,000,000USD-10,000,000USD-3,000,000USD-2,000,000USD———
    Net Income Applicable To Common Shares6,704,000,000USD6,335,000,000USD6,950,000,000USD7,725,000,000USD6,375,000,000USD3,696,000,000USD2,938,000,000USD2,225,000,000USD
    Net Interest Income—-312,000,000USD-454,000,000USD-493,000,000USD-488,000,000USD-452,000,000USD-530,000,000USD-511,000,000USD
    Tax Provision—657,000,000USD703,000,000USD1,109,000,000USD850,000,000USD374,000,000USD324,000,000USD201,000,000USD
    Net Income From Continuing Ops—6,338,000,000USD6,960,000,000USD7,728,000,000USD6,375,000,000USD3,696,000,000USD2,938,000,000USD2,228,000,000USD
    Ebit—8,692,000,000USD8,561,000,000USD9,377,000,000USD7,783,000,000USD4,746,000,000USD3,929,000,000USD3,021,000,000USD
    Ebitda—11,800,000,000USD11,942,000,000USD11,969,000,000USD10,108,000,000USD7,023,000,000USD6,195,000,000USD5,054,000,000USD
    Depreciation And Amortization—3,108,000,000USD3,381,000,000USD2,592,000,000USD2,325,000,000USD2,277,000,000USD2,266,000,000USD2,033,000,000USD
    Reconciled Depreciation—3,108,000,000USD3,381,000,000USD2,592,000,000USD2,325,000,000USD2,277,000,000USD2,267,000,000USD2,033,000,000USD
    Unclassified Operating Expenses——1,888,000,000USD1,068,000,000USD——92,000,000USD—
    Non Operating Income Net Other——-4,000,000USD-655,000,000USD-16,000,000USD152,000,000USD——
    Discontinued Operations———————-3,000,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-27 · USDQ1 20262026-03-28 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets113,174,000,000USD113,281,000,000USD110,343,000,000USD103,020,000,000USD101,230,000,000USD99,041,000,000USD97,321,000,000USD100,364,000,000USD
    Cash And Equivalents4,064,000,000USD3,254,000,000USD9,852,000,000USD1,982,000,000USD4,576,000,000USD4,134,000,000USD4,009,000,000USD4,645,000,000USD
    Cash And Short Term Investments4,064,000,000USD3,256,000,000USD10,105,000,000USD3,546,000,000USD6,393,000,000USD5,947,000,000USD5,580,000,000USD6,645,000,000USD
    Short Term Investments0USD2,000,000USD253,000,000USD1,564,000,000USD1,814,000,000USD1,813,000,000USD1,561,000,000USD2,000,000,000USD
    Total Current Assets23,365,000,000USD22,316,000,000USD28,707,000,000USD22,295,000,000USD24,584,000,000USD23,378,000,000USD22,137,000,000USD23,783,000,000USD
    Other Current Assets2,536,000,000USD2,677,000,000USD2,612,000,000USD2,473,000,000USD2,597,000,000USD2,386,000,000USD1,953,000,000USD1,912,000,000USD
    Other Non Current Assets5,616,000,000USD5,973,000,000USD5,871,000,000USD—————
    Total Liabilities60,367,000,000USD61,220,000,000USD56,806,000,000USD—————
    Total Current Liabilities15,069,000,000USD14,621,000,000USD15,189,000,000USD14,888,000,000USD12,718,000,000USD13,174,000,000USD13,332,000,000USD14,601,000,000USD
    Other Current Liabilities3,823,000,000USD3,694,000,000USD3,329,000,000USD—————
    Other Non Current Liabilities4,538,000,000USD4,421,000,000USD4,273,000,000USD—————
    Total Stockholder Equity52,679,000,000USD51,934,000,000USD53,407,000,000USD51,024,000,000USD50,511,000,000USD49,390,000,000USD49,584,000,000USD48,992,000,000USD
    Total Equity Including Noncontrolling Interest52,686,000,000USD52,061,000,000USD53,537,000,000USD—————
    Long Term Debt39,181,000,000USD40,071,000,000USD35,852,000,000USD31,857,000,000USD33,015,000,000USD31,370,000,000USD29,061,000,000USD31,197,000,000USD
    Deferred Revenue2,918,000,000USD2,928,000,000USD2,710,000,000USD—————
    Deferred Revenue Non Current1,043,000,000USD1,034,000,000USD1,183,000,000USD—————
    Net Receivables9,451,000,000USD9,204,000,000USD8,900,000,000USD10,531,000,000USD10,035,000,000USD9,821,000,000USD9,626,000,000USD9,796,000,000USD
    Inventory5,627,000,000USD5,496,000,000USD5,425,000,000USD5,745,000,000USD5,559,000,000USD5,224,000,000USD4,978,000,000USD5,430,000,000USD
    Property Plant Equipment Net10,755,000,000USD10,658,000,000USD12,012,000,000USD10,177,000,000USD9,635,000,000USD9,331,000,000USD10,795,000,000USD9,412,000,000USD
    Goodwill54,832,000,000USD55,187,000,000USD49,362,000,000USD—————
    Intangible Assets18,606,000,000USD19,146,000,000USD15,838,000,000USD16,242,000,000USD15,148,000,000USD15,323,000,000USD15,533,000,000USD16,262,000,000USD
    Accounts Payable3,268,000,000USD3,344,000,000USD3,622,000,000USD2,980,000,000USD2,980,000,000USD3,049,000,000USD3,079,000,000USD2,606,000,000USD
    Short Term Debt3,368,000,000USD3,090,000,000USD3,533,000,000USD3,823,000,000USD2,214,000,000USD2,819,000,000USD2,475,000,000USD4,116,000,000USD
    Common Stock446,000,000USD445,000,000USD445,000,000USD444,000,000USD444,000,000USD444,000,000USD444,000,000USD444,000,000USD
    Retained Earnings62,194,000,000USD60,632,000,000USD59,156,000,000USD55,901,000,000USD55,901,000,000USD54,447,000,000USD53,102,000,000USD51,421,000,000USD
    Accumulated Other Comprehensive Income-2,460,000,000USD-2,497,000,000USD-2,448,000,000USD-2,797,000,000USD-2,797,000,000USD-2,342,000,000USD-2,697,000,000USD-2,477,000,000USD
    Total Liab———51,996,000,000USD50,628,000,000USD49,555,000,000USD47,650,000,000USD51,265,000,000USD
    Other Current Liab———5,233,000,000USD4,719,000,000USD4,440,000,000USD4,926,000,000USD5,216,000,000USD
    Capital Stock———445,000,000USD444,000,000USD444,000,000USD444,000,000USD444,000,000USD
    Good Will———49,287,000,000USD47,249,000,000USD46,493,000,000USD45,853,000,000USD46,726,000,000USD
    Other Assets———5,018,000,000USD-1,000,000USD4,512,000,000USD4,486,000,000USD4,173,000,000USD
    Cash———1,982,000,000USD4,579,000,000USD4,134,000,000USD4,019,000,000USD4,645,000,000USD
    Current Deferred Revenue———2,852,000,000USD2,805,000,000USD2,866,000,000USD2,852,000,000USD2,663,000,000USD
    Net Debt———33,698,000,000USD30,650,000,000USD30,055,000,000USD28,766,000,000USD30,668,000,000USD
    Short Long Term Debt———3,823,000,000USD2,214,000,000USD2,819,000,000USD2,214,000,000USD4,116,000,000USD
    Short Long Term Debt Total———35,680,000,000USD35,229,000,000USD34,189,000,000USD32,775,000,000USD35,313,000,000USD
    Common Stock Shares Outstanding———378,000,000shares378,000,000shares379,000,000shares383,000,000shares384,000,000shares
    Non Current Assets Total———80,725,000,000USD76,646,000,000USD75,663,000,000USD75,184,000,000USD76,581,000,000USD
    Non Current Liabilities Total———37,108,000,000USD37,910,000,000USD36,382,000,000USD34,318,000,000USD36,664,000,000USD
    Non Current Liabilities Other———4,279,000,000USD4,271,000,000USD3,971,000,000USD3,988,000,000USD4,344,000,000USD
    Non Currrent Assets Other———4,584,000,000USD4,416,000,000USD4,142,000,000USD2,443,000,000USD4,075,000,000USD
    Net Working Capital———7,407,000,000USD11,866,000,000USD10,204,000,000USD8,805,000,000USD9,182,000,000USD
    Unclassified Non Current Assets———-4,583,000,000USD—-4,138,000,000USD-3,926,000,000USD-4,067,000,000USD
    Unclassified Current Liabilities———-3,823,000,000USD-2,214,000,000USD-2,819,000,000USD-2,214,000,000USD-4,116,000,000USD
    Unclassified Non Current Liabilities———972,000,000USD624,000,000USD1,041,000,000USD1,269,000,000USD1,123,000,000USD
    Unclassified Equity———-2,969,000,000USD-3,481,000,000USD-3,603,000,000USD-1,709,000,000USD-840,000,000USD
    Property Plant Equipment Gross——————16,059,000,000USD—
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets110,343,000,000USD97,321,000,000USD98,726,000,000USD97,154,000,000USD95,123,000,000USD69,052,000,000USD58,381,000,000USD56,232,000,000USD
    Cash And Equivalents9,852,000,000USD4,009,000,000USD8,077,000,000USD8,524,000,000USD4,477,000,000USD10,325,000,000USD2,399,000,000USD2,103,000,000USD
    Cash And Short Term Investments10,105,000,000USD5,580,000,000USD8,083,000,000USD8,524,000,000USD4,477,000,000USD10,325,000,000USD2,399,000,000USD2,103,000,000USD
    Short Term Investments253,000,000USD1,561,000,000USD-1,967,000,000USD2,000,000USD—28,000,000USD37,000,000USD3,000,000USD
    Total Current Assets28,707,000,000USD22,137,000,000USD24,589,000,000USD25,229,000,000USD20,113,000,000USD21,957,000,000USD11,893,000,000USD10,625,000,000USD
    Other Current Assets2,612,000,000USD1,953,000,000USD1,760,000,000USD1,644,000,000USD1,640,000,000USD1,131,000,000USD1,172,000,000USD922,000,000USD
    Other Non Current Assets5,871,000,000USD———————
    Total Liabilities56,806,000,000USD———————
    Total Current Liabilities15,189,000,000USD13,332,000,000USD14,012,000,000USD17,010,000,000USD13,436,000,000USD10,304,000,000USD6,197,000,000USD6,147,000,000USD
    Other Current Liabilities3,329,000,000USD———————
    Other Non Current Liabilities4,273,000,000USD———————
    Total Stockholder Equity53,407,000,000USD49,584,000,000USD46,735,000,000USD43,978,000,000USD40,793,000,000USD34,507,000,000USD29,675,000,000USD27,586,000,000USD
    Total Equity Including Noncontrolling Interest53,537,000,000USD———————
    Long Term Debt35,852,000,000USD29,061,000,000USD31,308,000,000USD28,909,000,000USD32,333,000,000USD19,107,000,000USD17,076,000,000USD17,719,000,000USD
    Deferred Revenue2,710,000,000USD———————
    Deferred Revenue Non Current1,183,000,000USD———————
    Net Receivables8,900,000,000USD9,626,000,000USD9,664,000,000USD9,427,000,000USD8,945,000,000USD6,472,000,000USD4,952,000,000USD4,595,000,000USD
    Inventory5,425,000,000USD4,978,000,000USD5,088,000,000USD5,634,000,000USD5,051,000,000USD4,029,000,000USD3,370,000,000USD3,005,000,000USD
    Property Plant Equipment Net12,012,000,000USD10,795,000,000USD11,004,000,000USD10,873,000,000USD9,864,000,000USD6,687,000,000USD5,448,000,000USD4,165,000,000USD
    Goodwill49,362,000,000USD———————
    Intangible Assets15,838,000,000USD15,533,000,000USD16,670,000,000USD17,478,000,000USD20,146,000,000USD12,685,000,000USD14,014,000,000USD14,978,000,000USD
    Accounts Payable3,622,000,000USD3,079,000,000USD2,872,000,000USD3,381,000,000USD2,867,000,000USD2,175,000,000USD1,920,000,000USD1,615,000,000USD
    Short Term Debt3,533,000,000USD2,475,000,000USD3,872,000,000USD5,851,000,000USD2,803,000,000USD2,812,000,000USD843,000,000USD1,271,000,000USD
    Common Stock445,000,000USD444,000,000USD442,000,000USD441,000,000USD439,000,000USD437,000,000USD434,000,000USD432,000,000USD
    Retained Earnings59,156,000,000USD53,102,000,000USD47,364,000,000USD41,910,000,000USD35,431,000,000USD28,116,000,000USD22,092,000,000USD18,696,000,000USD
    Accumulated Other Comprehensive Income-2,448,000,000USD-2,697,000,000USD-3,224,000,000USD-3,099,000,000USD-2,329,000,000USD-2,807,000,000USD-2,679,000,000USD-2,498,000,000USD
    Total Liab—47,650,000,000USD51,884,000,000USD53,006,000,000USD54,146,000,000USD34,535,000,000USD28,706,000,000USD28,646,000,000USD
    Other Current Liab—4,926,000,000USD4,579,000,000USD5,177,000,000USD5,111,000,000USD4,046,000,000USD2,518,000,000USD2,452,000,000USD
    Capital Stock—444,000,000USD442,000,000USD441,000,000USD439,000,000USD437,000,000USD434,000,000USD432,000,000USD
    Good Will—45,853,000,000USD44,020,000,000USD41,196,000,000USD41,924,000,000USD26,041,000,000USD25,714,000,000USD25,347,000,000USD
    Other Assets—2,956,000,000USD2,427,000,000USD2,224,000,000USD3,013,000,000USD1,629,000,000USD1,245,000,000USD1,053,000,000USD
    Cash—4,019,000,000USD8,083,000,000USD8,524,000,000USD4,477,000,000USD10,325,000,000USD2,399,000,000USD2,103,000,000USD
    Current Deferred Revenue—2,852,000,000USD2,689,000,000USD2,601,000,000USD2,655,000,000USD1,271,000,000USD916,000,000USD809,000,000USD
    Net Debt—28,766,000,000USD28,341,000,000USD27,549,000,000USD31,862,000,000USD12,220,000,000USD16,070,000,000USD16,875,000,000USD
    Short Long Term Debt—2,214,000,000USD3,609,000,000USD5,579,000,000USD2,537,000,000USD2,628,000,000USD676,000,000USD1,271,000,000USD
    Short Long Term Debt Total—32,775,000,000USD36,424,000,000USD36,073,000,000USD36,339,000,000USD22,545,000,000USD18,490,000,000USD18,990,000,000USD
    Property Plant Equipment Gross—16,059,000,000USD15,524,000,000USD14,269,000,000USD12,593,000,000USD5,912,000,000USD4,749,000,000USD4,165,000,000USD
    Common Stock Shares Outstanding—383,000,000shares388,000,000shares394,000,000shares397,000,000shares399,000,000shares403,000,000shares406,000,000shares
    Non Current Assets Total—75,184,000,000USD74,137,000,000USD71,925,000,000USD75,010,000,000USD47,095,000,000USD46,488,000,000USD45,607,000,000USD
    Non Current Liabilities Total—34,318,000,000USD37,872,000,000USD35,996,000,000USD40,710,000,000USD24,231,000,000USD22,509,000,000USD22,499,000,000USD
    Non Current Liabilities Other—3,988,000,000USD4,642,000,000USD7,119,000,000USD48,993,000,000USD3,340,000,000USD3,241,000,000USD2,515,000,000USD
    Non Currrent Assets Other—2,443,000,000USD2,384,000,000USD2,223,000,000USD3,003,000,000USD1,574,000,000USD1,277,000,000USD1,064,000,000USD
    Net Working Capital—8,805,000,000USD10,577,000,000USD8,251,000,000USD6,726,000,000USD11,653,000,000USD5,696,000,000USD4,478,000,000USD
    Unclassified Non Current Assets—-2,396,000,000USD-2,368,000,000USD-2,069,000,000USD-2,940,000,000USD-1,521,000,000USD-1,277,000,000USD-1,064,000,000USD
    Unclassified Current Liabilities—-2,214,000,000USD-3,609,000,000USD-5,579,000,000USD-2,537,000,000USD-2,628,000,000USD-676,000,000USD-1,271,000,000USD
    Unclassified Non Current Liabilities—1,269,000,000USD1,922,000,000USD-8,570,000,000USD-52,591,000,000USD-5,144,000,000USD-4,849,000,000USD-4,651,000,000USD
    Unclassified Equity—-1,709,000,000USD1,711,000,000USD4,285,000,000USD15,735,000,000USD15,142,000,000USD14,630,000,000USD14,189,000,000USD
    Unclassified Current Assets——1,961,000,000USD—————
    Deferred Long Term Liab———2,849,000,000USD3,837,000,000USD1,794,000,000USD2,192,000,000USD2,265,000,000USD
    Other Liab———5,689,000,000USD8,138,000,000USD5,134,000,000USD4,849,000,000USD4,651,000,000USD
    Net Tangible Assets———-14,544,000,000USD-21,182,000,000USD-4,219,000,000USD-10,053,000,000USD-12,739,000,000USD
    Treasury Stock————-8,922,000,000USD-6,818,000,000USD-5,236,000,000USD-3,665,000,000USD
    Long Term Investments——————67,000,000USD64,000,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-27 · USD
    Net Income3,397,000,000USD
    Depreciation1,553,000,000USD
    Stock Based Compensation165,000,000USD
    Deferred Income Tax-466,000,000USD
    Other Non Cash Items205,000,000USD
    Change In Working Capital-1,537,000,000USD
    Operating Cash Flow3,317,000,000USD
    Capital Expenditures-826,000,000USD
    Net Investments218,000,000USD
    Other Investing Activities683,000,000USD
    Unclassified Investing Cash Flow-8,872,000,000USD
    Investing Cash Flow-8,797,000,000USD
    Net Debt Issuance3,826,000,000USD
    Net Common Stock Issuance-4,000,000,000USD
    Common Dividends Paid-337,000,000USD
    Other Financing Activities33,000,000USD
    Financing Cash Flow-478,000,000USD
    Effect Of Forex Changes On Cash176,000,000USD
    Change In Cash-5,782,000,000USD
    End Cash Flow4,096,000,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-28 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Depreciation736,000,000USD728,000,000USD662,000,000USD685,000,000USD706,000,000USD740,000,000USD740,000,000USD790,000,000USD
    Stock Based Compensation83,000,000USD84,000,000USD70,000,000USD81,000,000USD75,000,000USD79,000,000USD68,000,000USD84,000,000USD
    Deferred Income Tax-258,000,000USD———————
    Other Non Cash Items-88,000,000USD97,000,000USD-2,068,000,000USD147,000,000USD206,000,000USD132,000,000USD89,000,000USD108,000,000USD
    Operating Cash Flow1,192,000,000USD———————
    Capital Expenditures-376,000,000USD-465,000,000USD-404,000,000USD-294,000,000USD-362,000,000USD-480,000,000USD-272,000,000USD-301,000,000USD
    Net Investments236,000,000USD———————
    Other Investing Activities-8,817,000,000USD———————
    Unclassified Investing Cash Flow-4,000,000USD-23,000,000USD300,000,000USD286,000,000USD275,000,000USD436,000,000USD271,000,000USD296,000,000USD
    Investing Cash Flow-8,961,000,000USD———————
    Net Debt Issuance3,826,000,000USD———————
    Net Common Stock Issuance-3,000,000,000USD———————
    Common Dividends Paid-162,000,000USD———————
    Other Financing Activities39,000,000USD———————
    Unclassified Financing Cash Flow390,000,000USD-2,849,000,000USD-2,498,000,000USD2,000,000,000USD——3,000,000,000USD—
    Financing Cash Flow1,093,000,000USD———————
    Effect Of Forex Changes On Cash78,000,000USD———————
    Change In Cash-6,599,000,000USD7,868,000,000USD-2,592,000,000USD431,000,000USD131,000,000USD-630,000,000USD-2,427,000,000USD1,578,000,000USD
    End Cash Flow3,280,000,000USD———————
    Net Income—1,970,000,000USD1,621,000,000USD1,615,000,000USD1,515,000,000USD1,824,000,000USD1,639,000,000USD1,548,000,000USD
    Change In Working Capital—489,000,000USD2,151,000,000USD-726,000,000USD-1,425,000,000USD594,000,000USD30,000,000USD-216,000,000USD
    Total Cash From Operating Activities—3,457,000,000USD2,239,000,000USD1,399,000,000USD723,000,000USD3,290,000,000USD2,166,000,000USD1,960,000,000USD
    Free Cash Flow—2,992,000,000USD1,835,000,000USD1,105,000,000USD361,000,000USD2,810,000,000USD1,894,000,000USD1,659,000,000USD
    Investments—1,329,000,000USD-4,123,000,000USD-288,000,000USD-527,000,000USD20,000,000USD-3,578,000,000USD-253,000,000USD
    Total Cashflows From Investing Activities—891,000,000USD-4,123,000,000USD-288,000,000USD-527,000,000USD20,000,000USD-3,578,000,000USD-253,000,000USD
    Net Borrowings—3,634,000,000USD498,000,000USD-787,000,000USD2,002,000,000USD-2,500,000,000USD-1,107,000,000USD—
    Total Cash From Financing Activities—3,526,000,000USD-632,000,000USD-991,000,000USD-102,000,000USD-3,666,000,000USD-1,190,000,000USD-114,000,000USD
    Dividends Paid—-162,000,000USD-163,000,000USD-162,000,000USD-149,000,000USD-149,000,000USD-150,000,000USD-149,000,000USD
    Sale Purchase Of Stock—-3,000,000,000USD2,000,000,000USD-2,000,000,000USD-2,000,000,000USD-1,000,000,000USD-3,000,000,000USD0USD
    Begin Period Cash Flow—2,011,000,000USD4,603,000,000USD4,172,000,000USD4,040,000,000USD4,670,000,000USD7,084,000,000USD5,506,000,000USD
    End Period Cash Flow—9,879,000,000USD2,011,000,000USD4,603,000,000USD4,172,000,000USD4,040,000,000USD4,670,000,000USD7,084,000,000USD
    Other Cashflows From Investing Activities—50,000,000USD104,000,000USD8,000,000USD87,000,000USD44,000,000USD1,000,000USD5,000,000USD
    Other Cashflows From Financing Activities—5,903,000,000USD-469,000,000USD-42,000,000USD45,000,000USD-17,000,000USD67,000,000USD36,000,000USD
    Unclassified Operating Cash Flow—89,000,000USD-197,000,000USD-403,000,000USD-354,000,000USD-79,000,000USD-400,000,000USD-354,000,000USD
    Change To Account Receivables—————-333,000,000USD——
    Change To Inventory—————-27,000,000USD——
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Depreciation2,780,000,000USD3,108,000,000USD3,406,000,000USD3,381,000,000USD2,592,000,000USD2,325,000,000USD2,277,000,000USD2,267,000,000USD
    Stock Based Compensation310,000,000USD301,000,000USD278,000,000USD307,000,000USD230,000,000USD196,000,000USD181,000,000USD181,000,000USD
    Deferred Income Tax-639,000,000USD———————
    Other Non Cash Items-455,000,000USD463,000,000USD564,000,000USD550,000,000USD957,000,000USD340,000,000USD-214,000,000USD106,000,000USD
    Change To Account Receivables-426,000,000USD-171,000,000USD209,000,000USD-430,000,000USD-204,000,000USD-1,302,000,000USD-225,000,000USD-366,000,000USD
    Change To Inventory-74,000,000USD-27,000,000USD598,000,000USD-825,000,000USD-1,065,000,000USD-508,000,000USD-458,000,000USD-324,000,000USD
    Change To Liabilities421,000,000USD——648,000,000USD479,000,000USD59,000,000USD476,000,000USD159,000,000USD
    Change In Working Capital-79,000,000USD-334,000,000USD-537,000,000USD-1,049,000,000USD-1,558,000,000USD-395,000,000USD-619,000,000USD-530,000,000USD
    Operating Cash Flow7,818,000,000USD———————
    Capital Expenditures-1,525,000,000USD-1,400,000,000USD-1,479,000,000USD-2,243,000,000USD-2,523,000,000USD-1,474,000,000USD-926,000,000USD-758,000,000USD
    Net Investments1,182,000,000USD———————
    Other Investing Activities-4,058,000,000USD———————
    Unclassified Investing Cash Flow354,000,000USD1,083,000,000USD1,701,000,000USD2,159,000,000USD2,557,000,000USD1,510,000,000USD1,487,000,000USD717,000,000USD
    Investing Cash Flow-4,047,000,000USD———————
    Net Debt Issuance5,347,000,000USD———————
    Net Common Stock Issuance-3,000,000,000USD———————
    Common Dividends Paid-636,000,000USD———————
    Other Financing Activities90,000,000USD———————
    Financing Cash Flow1,801,000,000USD———————
    Effect Of Forex Changes On Cash267,000,000USD———————
    Change In Cash5,839,000,000USD-4,057,000,000USD-440,000,000USD4,046,000,000USD-5,845,000,000USD7,914,000,000USD305,000,000USD756,000,000USD
    End Cash Flow9,879,000,000USD———————
    Net Income—6,338,000,000USD5,995,000,000USD6,960,000,000USD7,728,000,000USD6,375,000,000USD3,696,000,000USD2,938,000,000USD
    Total Cash From Operating Activities—8,667,000,000USD8,406,000,000USD9,154,000,000USD9,543,000,000USD8,289,000,000USD4,973,000,000USD4,543,000,000USD
    Free Cash Flow—7,267,000,000USD6,927,000,000USD6,911,000,000USD7,020,000,000USD6,815,000,000USD4,047,000,000USD3,785,000,000USD
    Investments—-5,841,000,000USD-5,291,000,000USD-2,159,000,000USD-21,932,000,000USD-1,510,000,000USD-1,487,000,000USD-1,253,000,000USD
    Total Cashflows From Investing Activities—-5,841,000,000USD-5,142,000,000USD-2,159,000,000USD-21,932,000,000USD-1,510,000,000USD-1,487,000,000USD-1,253,000,000USD
    Net Borrowings—-2,403,000,000USD-155,000,000USD654,000,000USD8,911,000,000USD2,747,000,000USD-1,405,000,000USD-1,556,000,000USD
    Total Cash From Financing Activities—-6,792,000,000USD-3,622,000,000USD-2,810,000,000USD6,581,000,000USD959,000,000USD-3,118,000,000USD-2,237,000,000USD
    Dividends Paid—-583,000,000USD-523,000,000USD-455,000,000USD-395,000,000USD-337,000,000USD-297,000,000USD-266,000,000USD
    Sale Purchase Of Stock—-4,000,000,000USD-3,000,000,000USD-3,000,000,000USD-2,000,000,000USD-1,500,000,000USD-1,500,000,000USD-500,000,000USD
    Begin Period Cash Flow—8,097,000,000USD8,537,000,000USD4,491,000,000USD10,336,000,000USD2,422,000,000USD2,117,000,000USD1,361,000,000USD
    End Period Cash Flow—4,040,000,000USD8,097,000,000USD8,537,000,000USD4,491,000,000USD10,336,000,000USD2,422,000,000USD2,117,000,000USD
    Other Cashflows From Investing Activities—317,000,000USD-73,000,000USD84,000,000USD-34,000,000USD-36,000,000USD-561,000,000USD41,000,000USD
    Other Cashflows From Financing Activities—194,000,000USD56,000,000USD4,710,000,000USD-91,000,000USD-147,000,000USD8,350,000,000USD85,000,000USD
    Unclassified Operating Cash Flow—-1,209,000,000USD-1,300,000,000USD-995,000,000USD-406,000,000USD-552,000,000USD-348,000,000USD-419,000,000USD
    Cash And Cash Equivalents Changes———4,185,000,000USD-6,039,000,000USD7,738,000,000USD368,000,000USD1,053,000,000USD
    Unclassified Financing Cash Flow———-4,719,000,000USD156,000,000USD196,000,000USD-8,266,000,000USD—
    Issuance Of Capital Stock——————153,000,000USD0USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    RPO Expected Within Next 12 Months

    Period endPeriodValueUnitSource
    2026-06-27instant52percentDisclosure

    Remaining Performance Obligations

    Period endPeriodValueUnitSource
    2026-06-27instant29,700,000,000USDDisclosure

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-27GeographyAsia Pacific2,104,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-27GeographyEurope3,311,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-27GeographyNorth America6,149,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-27GeographyOther Regions430,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-27ProductOther565,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-27ProductProduct Consumables5,073,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-27ProductProduct Instruments1,750,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-27ProductServices5,171,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-27SegmentAnalytical Instruments1,799,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-27SegmentLaboratory Products And Biopharma Services6,652,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-27SegmentLife Sciences Solutions2,355,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-27SegmentSpecialty Diagnostics1,188,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-28GeographyAsia Pacific1,970,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-28GeographyEurope2,957,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-28GeographyNorth America5,705,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-28GeographyOther Regions372,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-28ProductConsumables4,722,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-28ProductInstruments1,555,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-28ProductOther524,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-28ProductServices4,728,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-28SegmentAnalytical Instruments1,667,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-28SegmentLaboratory Products And Biopharma Services5,995,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-28SegmentLife Sciences Solutions2,219,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-28SegmentSpecialty Diagnostics1,124,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductConsumables18,664,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductInstruments7,301,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductOther2,032,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductServices18,592,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31SegmentAnalytical Instruments7,353,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31SegmentLaboratory Products And Biopharma Services23,818,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31SegmentLife Sciences Solutions8,781,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31SegmentSpecialty Diagnostics4,604,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30GeographyAsia Pacific2,013,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30GeographyEurope3,005,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30GeographyNorth America5,689,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30GeographyOther Regions415,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30SegmentAnalytical Instruments1,847,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30SegmentLaboratory Products And Biopharma Services5,927,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30SegmentLife Sciences Solutions2,194,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30SegmentSpecialty Diagnostics1,154,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30GeographyAsia Pacific1,920,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30GeographyEurope2,830,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30GeographyNorth America5,722,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30GeographyOther Regions383,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30ProductConsumables4,606,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30ProductInstruments1,644,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30ProductOther501,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30ProductServices4,605,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30SegmentAnalytical Instruments1,669,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30SegmentLaboratory Products And Biopharma Services5,953,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30SegmentLife Sciences Solutions2,115,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30SegmentSpecialty Diagnostics1,118,000,000USDDisclosure
    Q4 2024Quarterly · 2024-12-31ProductConsumables4,517,000,000USDDisclosure
    Q4 2024Quarterly · 2024-12-31ProductInstruments2,250,000,000USDDisclosure
    Q4 2024Quarterly · 2024-12-31ProductOther489,000,000USDDisclosure
    Q4 2024Quarterly · 2024-12-31ProductServices4,627,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31ProductConsumables17,587,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31ProductInstruments7,446,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31ProductOther1,886,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31ProductServices17,845,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31SegmentAnalytical Instruments7,267,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31SegmentLaboratory Products And Biopharma Services23,002,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31SegmentLife Sciences Solutions8,160,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31SegmentSpecialty Diagnostics4,449,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30GeographyAsia Pacific1,923,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30GeographyEurope2,686,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30GeographyNorth America5,591,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30GeographyOther Regions397,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30ProductConsumables4,379,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30ProductInstruments1,769,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30ProductOther467,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30ProductServices4,450,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30SegmentAnalytical Instruments1,776,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30SegmentLaboratory Products And Biopharma Services5,701,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30SegmentLife Sciences Solutions2,009,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30SegmentSpecialty Diagnostics1,111,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30GeographyAsia Pacific1,971,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30GeographyEurope2,663,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30GeographyNorth America5,529,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30GeographyOther Regions379,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30ProductConsumables4,363,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30ProductInstruments1,800,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30ProductOther470,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30ProductServices4,378,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30SegmentAnalytical Instruments1,727,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30SegmentLaboratory Products And Biopharma Services5,719,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30SegmentLife Sciences Solutions1,996,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30SegmentSpecialty Diagnostics1,100,000,000USDDisclosure
    Q1 2024Quarterly · 2024-03-31GeographyAsia Pacific1,861,000,000USDDisclosure
    Q1 2024Quarterly · 2024-03-31GeographyEurope2,619,000,000USDDisclosure
    Q1 2024Quarterly · 2024-03-31GeographyNorth America5,519,000,000USDDisclosure
    Q1 2024Quarterly · 2024-03-31GeographyOther Regions346,000,000USDDisclosure
    Q1 2024Quarterly · 2024-03-31ProductConsumables4,328,000,000USDDisclosure
    Q1 2024Quarterly · 2024-03-31ProductInstruments1,627,000,000USDDisclosure
    Q1 2024Quarterly · 2024-03-31ProductOther460,000,000USDDisclosure
    Q1 2024Quarterly · 2024-03-31ProductServices4,390,000,000USDDisclosure
    Q4 2023Quarterly · 2023-12-31ProductConsumables4,369,000,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductInstruments2,042,000,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductOther1,829,000,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductServices4,475,000,000USDLegacy provider

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.